Analysis of radiation-induced liver disease using the Lyman NTCP model.

Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109-0010, USA.
International Journal of Radiation OncologyBiologyPhysics (Impact Factor: 4.52). 07/2002; 53(4):810-21. DOI: 10.1016/S0360-3016(02)02846-8
Source: PubMed

ABSTRACT To describe the dose-volume tolerance for radiation-induced liver disease (RILD) using the Lyman-Kutcher-Burman (LKB) normal tissue complication probability (NTCP) model.
A total of 203 patients treated with conformal liver radiotherapy and concurrent hepatic arterial chemotherapy were prospectively followed for RILD. Normal liver dose-volume histograms and RILD status for these patients were used as input data for determination of LKB model parameters. A complication was defined as Radiation Therapy Oncology Group Grade 3 or higher RILD < o r =4 months after completion of radiotherapy. A maximal likelihood analysis yielded best estimates for the LKB NTCP model parameters for the liver for the entire patient population. A multivariate analysis of the potential factors associated with RILD was also completed, and refined LKB model parameters were obtained for patient subgroups with different risks of RILD.
Of 203 patients treated with focal liver irradiation, 19 developed RILD. The LKB NTCP model fit the complication data for the entire group. The "n" parameter was larger than previously described, suggesting a strong volume effect for RILD and a correlation of NTCP with the mean liver dose. No cases of RILD were observed when the mean liver dose was <31 Gy. Multivariate analysis demonstrated that in addition to NTCP and the mean liver dose, a primary hepatobiliary cancer diagnosis (vs. liver metastases), bromodeoxyuridine hepatic artery chemotherapy (vs. fluorodeoxyuridine chemotherapy), and male gender were associated with RILD. For 169 patients treated with fluorodeoxyuridine, the refined LKB model parameters were n = 0.97, m = 0.12, tolerance dose for 50% complication risk for whole organ irradiated uniformly [TD50(1)] = 45.8 Gy for patients with liver metastases, and TD50(1) = 39.8 Gy for patients with primary hepatobiliary cancer.
These data demonstrate that the liver exhibits a large volume effect for RILD, suggesting that the mean liver dose may be useful in ranking radiation plans. The inclusion of clinical factors, especially the diagnosis of primary hepatobiliary cancer vs. liver metastases, improves the estimation of NTCP over that obtained solely by the use of dose-volume data. These findings should facilitate the application of focal liver irradiation in future clinical trials.

1 Bookmark
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Radioembolization (RE) of liver cancer with (90)Y-microspheres has been applied in the last two decades with notable responses and acceptable toxicity. Two types of microspheres are available, glass and resin, the main difference being the activity/sphere. Generally, administered activities are established by empirical methods and differ for the two types. Treatment planning based on dosimetry is a prerogative of few centers, but has notably gained interest, with evidence of predictive power of dosimetry on toxicity, lesion response, and overall survival (OS). Radiobiological correlations between absorbed doses and toxicity to organs at risk, and tumor response, have been obtained in many clinical studies. Dosimetry methods have evolved from the macroscopic approach at the organ level to voxel analysis, providing absorbed dose spatial distributions and dose-volume histograms (DVH). The well-known effects of the external beam radiation therapy (EBRT), such as the volume effect, underlying disease influence, cumulative damage in parallel organs, and different tolerability of re-treatment, have been observed also in RE, identifying in EBRT a foremost reference to compare with. The radiobiological models - normal tissue complication probability and tumor control probability - and/or the style (DVH concepts) used in EBRT are introduced in RE. Moreover, attention has been paid to the intrinsic different activity distribution of resin and glass spheres at the microscopic scale, with dosimetric and radiobiological consequences. Dedicated studies and mathematical models have developed this issue and explain some clinical evidences, e.g., the shift of dose to higher toxicity thresholds using glass as compared to resin spheres. This paper offers a comprehensive review of the literature incident to dosimetry and radiobiological issues in RE, with the aim to summarize the results and to identify the most useful methods and information that should accompany future studies.
    Frontiers in oncology. 01/2014; 4:210.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Historically, Radiation Therapy (RT) has played a minor role in the treatment of hepatocellular carcinoma, especially because of toxicity related to conventional techniques. However, high radiation doses can now be given safely by means of 3D-conformal techniques and other more specialized techniques. 3D-conformal RT, in which both target definition and treatment planning are based on three-dimensional image data sets, provided good local control in several series. As an evolution of cranial radiosurgery, stereotactic body radiation therapy (SBRT) is currently being employed as a new tool for the treatment of HCC, as it offers the opportunity of achieving radioablation for tumors up to 6 cm in diameter with a minimal risk of radiation induced liver disease. SBRT is distinguished by the fact that both planning and treatment are guided by reference to a system of external stereotactic coordinates. As a consequence, SBRT may succeed in minimizing geometric treatment uncertainties, thus allowing the delivery of high doses to the target, given in a small number of fractions. In several published series of SBRT for HCC, actuarial 5-year local control rates higher than 80% have been achieved In short, radiation therapy should be considered as a useful addition to the treatment spectrum of HCC.
    Annali italiani di chirurgia 01/2008; 79(2):107-10. · 0.29 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cyberknife® is a dedicated stereotactic radiotherapy device. This new technology permits precise delivery of high dose gradient radiation therapy while sparing the surrounding organs at risk. Hepatic metastases of colorectal cancer (HMCRC) are an example of a lesion where treatment with Cyberknife® is indicated because they are located in a radio-sensitive organ and curative treatment is based on focal eradication (resection, radiofrequency ablation,…). The local control rate at one year is reported to be 70 to 100% depending on the study. Tolerance is excellent with less than a 5% rate of acute grade 3 or 4 side effects (nausea, vomiting, gastro-duodenal ulcer). The specific hepatotoxicity of radiotherapy, so-called radiation-induced liver disease (RILD), was found in only one study. Candidates for stereotactic radiotherapy are patients in whom disease is controlled except for intrahepatic disease with 1–3 hepatic metastases ≤ 6 cm in size who have contraindications for surgery, a WHO stage ≤ 2, a volume of healthy liver ≥ 700 cm3 and normal liver function. It is actually a very simple treatment that results in very good local control with few contraindications. Its place in the management strategy of liver metastases needs further clarification.
    Journal of Visceral Surgery 01/2014; · 1.17 Impact Factor

Full-text (2 Sources)

Available from
Jun 10, 2014